Acylaminoacyl-peptide hydrolase (APEH), a serine peptidase
that
belongs to the prolyl oligopeptidase (POP) family, catalyzes removal
of N-terminal acetylated amino acid residues from peptides. As a key
regulator of protein N-terminal acetylation, APEH was involved in
many important physiological processes while its aberrant expression
was correlated with progression of various diseases such as inflammation,
diabetics, Alzheimer’s disease (AD), and cancers. However,
while emerging attention has been attracted in APEH-related disease
diagnosis and drug discovery, the mechanisms behind APEH and related
disease progression are still unclear; thus, further investigating
the physiological role and function of APEH is of great importance.
To date, enzyme-activated fluorescent probes targeting POPs have been
extensively reported and adopted in relevant medical research and
applications. Nevertheless, as an important member of the POP family,
APEH was rarely referred in the field of bioimaging while the fluorescent
probe for in vivo sensing of APEH activity has not
been reported yet. Thus, acquiring an efficient APEH-targeted probe
is in urgent need. Herein, an enzyme-activated fluorogenic probe for in vivo profiling of APEH was first discovered via a substrate
mimic-based strategy. By combination of stimulated molecular docking-based
preliminary screening and experiment-based secondary screening, the
optimal probe (named as TMN-AcA), which displayed high
binding affinity, sensitivity, and specificity toward APEH, was screened
out. Owing to the superior properties of TMN-AcA, endogenous
APEH activity in various cell lines and transplanted tumor could be
visualized while tissue distribution of APEH was revealed. Most importantly,
APEH was first demonstrated to be a potential biomarker of multiple-organ
injury via TMN-AcA-based bioimaging and immunohistochemistry
(IHC) analysis while the newly developed probe could serve as a vital
tool for APEH-related disease diagnosis and biological function study.